INDEX OF AUTHORS

Aho, K., 1094
Albrecht, M., 1053
Allen, D. J., 1123
Anderson, J. A., 29
Astorga, G., 511
Atwater, E. C., 1080
Austen, K. F., 219

Baldes, E. J., 29
Barnett, E. V., 1080
Bartholomew, L. E., 376
Beetham, W. P., Jr., 355
Benedek, T. G., 560
Bennett, R. L., 1006
Binette, J. P., 14
Bloch, K. J., 219
Blumberg, B. S., 627
Bollet, A. J., 511
Bowie, M. A., 233
Brewer, E. J., Jr., 1152
Buchanan, W. W., 361

Caner, J. E. Z., 757
Carpenter, R. R., 213
Casagrande, P. A., 294
Cathcart, E. S., 530
Catsoulis, E. A., 38
Chrisman, O. D., 960
Christian, C. L., 1094
Clayton, M. L., 299, 566
Cleveland, S. E., 1152
Cobb, S., 76
Condemi, J. J., 1080
Correa, E. T., 501
Cross, R., 355

deAndrade, J. R., 294
Decker, J. L., 260, 840
Demartini, F. E., 823
Denko, C. W., 970
Dingle, J. H., 524
Dorner, R. W., 368
Drenick, E. J., 988
Dugan, A., 233
Duncan, H., 943
Dushkin, M., 1

Engleman, E. P., 1
Eyring, E. J., 1

Ford, D. K., 1047
Fostiropoulos, G., 219

Franklin, E. C., 38
Freudweiler, M., 267
Freyberg, R. H., 1159
Frost, H. M., 943

Gantner, G. E., Jr., 368
Gatter, R. A., 551
Gerber, D., 1104
Goldberg, R., 194
Goldfinger, S. E., 1112
Guasch, J. L., 501
Gutman, A. B., 614, 665, 911

Hall, A. P., 846
Harken, D. E., 413
Hidalgo, J. U., 976
Holman, H. R., 183
Hopper, J., Jr., 1
Houpt, J. B., 899
Howell, D. S., 337, 736, 998, 1024, 1039
Howell, R. R., 749, 780, 1112
Howes, R. G., 495

Jacox, R. F., 1053, 1080
Jaffe, I. A., 1064
Jarvis, B., 495
Johnson, L. G., 389

Katz, D., 61
Kellermeyer, R. W., 741
Kellgren, J. H., 568
Kim, S. O., 389
Klein, L., 61
Klinenberg, J. R., 361, 891
Kopell, H. P., 299
Krakoff, I. H., 772, 836, 896

Lamont-Havers, R. W., 598
Lange, K., 244, 403
Lee, J. C., 1
Lefkovits, A. M., 1019
Lieber, C. S., 786
Linn, F. C., 481
Lipson, R. L., 29, 80
Litwin, S. D., 538

Magasanik, B., 610
Malawista, S. E., 752
Marinetti, G. V., 1053
Marquez, J. F., 1039
Martin, J. R., 389
Masi, A. T., 418

Mattocks, A. M., 1123
Maxfield, W. S., 976
McCarty, D. J., Jr., 551, 726
Meilman, E., 69
Mikkelsen, W. M., 853
Milch, R. A., 1002
Milgrom, F., 203
Milosovich, G., 1123
Mongan, E. S., 1080, 1145
Mortimer, E. A., Jr., 501
Moskowitz, R. W., 61
Mudge, G. H., 686
Mullinax, F., 50
Murison, P. J., 976

Niedermeier, W., 355
Nugent, C. A., 671
Nyhan, W. L., 659

Ochsner, J. L., 403
Ogryzlo, M. A., 799
Oh, J. O., 1047
Oratz, M., 38
Ores, R., 244
O'Sullivan, J. B., 530

Patri, A. M., 501
Phelps, P., 551
Pita, J. C., 1039
Plotz, C. M., 194
Polley, H. F., 29, 581
Prokopová-Roubalová, D., 955

Rapoport, C., 69
Raymond, F. D., 233
Reitman, E. E., 1152
Ricca, L. R., 998
Robinson, W. D., 865
Rodnan, G. P., 599, 1024
Root, H. S., 389
Ropes, M. W., 566
Rothschild, M. A., 38
Ruhl, M. J., 97

Salzman, R. T., 998
Scherrer, J., 1104
Schmid, K., 14
Schuster, A. C., 501
Scott, J. F., 1027
Seegmiller, J. E., 361, 714, 1112
Shalit, I. E., 260
Short, C. L., 299
Shulman, L. E., 418
Sigler, J. W., 943
Simmons, D. P., 960
Singer, J. M., 194, 538
Slocumb, C. H., 80
Smyth, C. J., 907, 921
Smythe, H. A., 413
Sokoloff, L., 97, 481, 707, 1027
Sorensen, L. B., 694
Strauss, W., 244
Sturgill, B. C., 213
Svec, K. H., 524

Talbott, J. H., 87
Tesárek, B., 955
Thompson, G. R., 830, 1134
Thurman, L., 50
Tönder, O., 203
Toone, E. C., 50

Uddin, J., 368
Urivetsky, M., 69

Vaisman, S. B., 501
Varney, D. A., 1027
Vaughan, J. H., 1053, 1080
Vignau, A. I., 501
Villanueva, A. R., 943

Wachstein, M., 244
Wallace, S. L., 87, 744, 1104
Waller, M., 50
Wechsler, R., 1104
Weinberger, H., 413
Weiss, T. E., 403, 976
Willkens, R. F., 260
Wilske, K. R., 260
Wyngaarden, J. B., 87, 648, 883

Yü, T.-F., 765, 905

Ziff, M., 1161
Zuckner, J., 368
Zvaifler, N. J., 289
Zweifler, A. J., 1134

INDEX OF SUBJECTS

(Page numbers in *italics* refer to abstracts)

Acetaldehyde, alcohol converted to, 789
Acetoacetate, and uric acid clearance, 781, 800, 819
Acetone, and uric acid clearance, 799, 800, 819
Acidity of urine, in gout, 620, 625, 670
Acidosis, diabetic
  and hyperuricemia, 800, 853
  polymorphonuclear leukocytes in, 844
ACTH, uricosuric effect of, 723
Adenine, cellular incorporation of, in leukemias, 774
Adenine nucleotides, action of, 611
Adenosine 5'-phosphate (AMP), production of, 610, 652
Adjuvant disease
  cyclic exacerbations and remissions of, *460*
  as model of rheumatoid disease, *452*
Adrenal steroid therapy. *See* Steroid therapy
Aged persons
  anti-gamma globulin factors in, 538–548
  hydroxyproline excretion in, 61–67
Agglutination enhancing activity of rheumatoid factor, complement affecting, *467*
Agglutination test, standardization of, 530–536
A/J mice
  histopathology of, *458*
  inhibition of autoimmunity in, *474*
Alanine, affecting uric acid excretion, 800
Albumin, serum, radioiodinated, in rheumatoid arthritis joint studies, 976–987
Alcaptonuria, studies of, 1002–1005
Alcohol
  affecting lactate levels in blood, 787–791
  affecting liver, 794
  affecting uric acid levels, *454*
  hyperuricemia from, 786–798
  inhibiting antidiuretic hormone, 797
Alcohol dehydrogenase, 789, 796
Allantoic acid, production of, 696, 697
Allantoin, production of, 616, 667, 696, 697, 749
Allergy to gold therapy, 1–11
Allogeneic transplant antigen injections, amyloidosis after, *438*
Allopurinol
  in gout, 875, 883–910, 919
    in primary gout, 905–906
    in secondary gout, 905–906
    with sulfinpyrazone, 903, 905, 908
    in tophaceous gout, 900, 903, 907–910
  in leukemias and lymphomas, 896–898
  and uric acid levels, 682, 734
Alloxan, formation from uric acid, 701, 705
Aluminum hydroxide or carbonate, and intestinal phosphate absorption, 842
American Rheumatism Association
  amalgamation with Arthritis Foundation, 587
  annual meeting of Arthritis Foundation, 1163
  Clark resigns as editor, 1159–1160
  Decker appointed to NIAMD, 1164
  Eleventh Interim Scientific Session, 93
  Gairdner Award, 1164
  highlights of annual meeting, 479
  International Congress, 479
  Lamont-Havers in NIH post, 94
  McCarty as journal editor, 479, 1161–1162
  McCarty receives award, 1164–1165
  Medical Administrative Committee, 1163
  new officers and honorary members, 587
  new publications, 94
  Nuffield Rheumatism Conference, 1164
  Paramedical Section formed, 1164
  presidential address, 581–585
  proceedings of annual meeting, 427–478
  reference samples of rheumatoid factors, 588
  symposium to be held in March, 1164
  Ziff elected president, 586
Amidotransferase, and purine biosynthesis, 613, 619, 624, 652, 655
Amino acids
  drugs affecting clearance of, 693
  metabolism in gout, 614–621
  and uric acid clearance, 692–693, 800, 815
β-Amino-isobutyric acid, excretion of, 630–632
Ammonia
  excretion of
    in fasting state, 803–814
    in gout, 624
  formation of, factors in, 623
  production of, in gout, 614–621, 654
  as uricolytic product, 696, 697, 702
Ammonium chloride
  affecting uric acid excretion, 831–835
  in thiazide hyperuricemia, 1134–1143

Ammonotelism, 615, 618
Amyloid fibrils, immunologic studies of, *435*
Amyloidosis, after allogeneic transplant antigen injection, *438*
Anabolic agents, affecting osseous tissue, 955–959
Anemia, in rheumatoid arthritis, 233–242
Angiotensin, and uric acid clearance, 824, 826
Antibodies
  anti-DNA, in lupus erythematosus, *446*
  antinuclear. *See* Antinuclear factors
  anti-nucleoprotein, spontaneous, *458*
  incomplete, studies of, 1094–1103
  red-cell auto-antibody in NZB/Bl mice, *446*
  to ribosomes, in lupus erythematosus, 213–218
  in Sjögren's syndrome, 970–974
Anticonvulsant therapy, lupus erythematosus from, 260–265
Antidiuretic hormone, alcohol affecting, 797
Antigenicity of salivary mucins, *461*
Antigens
  amyloidosis after allogeneic transplant antigen injection, *438*
  streptococcal, in leukocyte cultures, *437*
Antiglobulin, Watson's, *441*
Antinuclear factor
  absence of, with abnormal L.E. cell test, *470*
  in childhood, *450*
  compared with intradermal tests in diseases, *428*
  in lupus erythematosus, *443*, *476*
  in myasthenia gravis, *476*
  in rheumatoid arthritis, 1080–1093
  as test in rheumatic disease, *463*
Anti-nucleoprotein antibody, spontaneous, *458*
Anturane. See Sulfinpyrazone
Apresoline
  affecting collagen synthesis, 69–74
  syndrome from, 69, 260
Arginine, affecting uric acid excretion, 800
Arthrotripsometer, *453*
Articular conditions. *See* Joints
Aspartic acid, affecting uric acid excretion, 800
Atherosclerosis, and gout, 709, 852
Autoimmunity in A/J mice, inhibition of, *474*
Avascular necrosis, and fat embolization, *448*
Azaserine, and uric acid production, 837, 883

Back pain, and gout, 712
BAL therapy, in gout, 745
Bauer Memorial Lecture, 183–193
Benemid. *See* Probenecid
Bentonite-ribosome flocculation tests, 213–218
Benzalkonium chloride, affecting urate crystal growth, 1125, 1129
Benzoic acid, affecting uric acid excretion, 800
Bicarbonate, sodium, and uric acid levels in serum, 807
Bile, uric acid in, 703, 704
Bismarck brown, affecting urate crystal growth, 1125, 1129
Blood flow, in connective tissue disease, *469*
Blood pressure, levels of, and hyperuricemia, 846, 849, 851
Book reviews
  Gout (*Talbott*), 91
  The Hand as a Mirror of Systemic Disease *(Berry)*, 426
  Orthopaedic Surgery *(Mercer & Duthie)*, 91
  Textbook of the Rheumatic Diseases *(Copeman, ed.)*, 91
Bradykinin, in gouty arthritis, 720
Butazolidine. *See* Phenylbutazone

Calcific periarthritis, in multiple sites, *462*
Calcific tendonitis, simulating acute gout, *475*
Calcinosis, and acute gout, 730
Calcium levels, and uric acid retention, 829, 841–842
Calculi
  uric acid
    in nongouty subjects, 624–625, 669
    in secondary gout, 766–767
    in starvation, 988–996
    and uric acid excretion, *669*
    from uricosuric agents, 870, 873, 875, 879
  urinary, and gout, 602, 603
  xanthine, 898, 906
Caner-Decker syndrome, 730
Carbamyl phosphate, in biosynthesis of pyrimidines, 616
Carbohydrates
  tolerance in gouty subjects, 854, 860
  and uric acid excretion, 800, 803, 815

Carbon dioxide
combining power of plasma, in fasting state, 803–814
as uricolytic product, 697, 698, 702
Carboxypeptidase, after bradykinin injection, 720
Carcinoma, metastatic, and lysis of patella, 560–567
Cardiac conduction defects, in ankylosing spondylitis, *476*
Cardiac disease
with rheumatoid arthritis, 403–417
uric acid levels in, 847–848, 855, 857
Carrageenin granuloma, hydralazine action in, 69–74
Cartilage
articular
cortisol affecting glycine incorporation into, *455*
studies of, *445*
epiphyseal, from rachitic rats, *447*
interstitial fluid of, 481–493
salicylate inhibition of degeneration, 960–968
urate crystals in, 708, 710–711, 723
Catalase, and uric acid oxidation, 701
Cecil, Russell L., 577–580
Cerebral function disorder, with uric acid metabolism defect, 659–663
Cervical spine
in mongolism, *455*
rheumatoid arthritis of, radiology of, *431*
Charcot's joints, staphylococcus suppurative arthritis in, 389–401
Chemotaxis of leukocytes, colchicine affecting, 746, 757–759
Childhood
antinuclear antibodies in, *450*
gonococcal arthritis in, *442*
See also Rheumatoid arthritis, juvenile
Chloroquine, ototoxicity of, *474*
Chlorothiazide
and amino acid clearance, 693
hyperuricemia from, 824, 827, 829, 830, 1134–1143
Chlorprothixene, uricosuric effects of, 880
Cholesterol
metabolism of, in gout, 709
serum levels, and uric acid levels, *430*, 849, 851
synthesis of, and alcohol oxidation, 789
Chondrocalcinosis, and complement in synovial fluid, 225
Chondrocytes, urate deposits on, 711
Chondroitin sulfate
loss from osteoarthritic cartilage, hyaluronidase affecting, *433*
and sodium urate solubility, 708
Cineradiography of rheumatoid arthritis of cricoarytenoid joint, *441*
Circulation, in connective tissue diseases, *469*
Clark, William S., 1159–1160
Classification of patients, in peripheral rheumatoid arthritis, 302–334
Colchiceine, 744, 746
Colchicine
action mechanisms of, 744–748
affecting leukocytes, 745–746, 749, 760–761, 1104–1111
affecting nervous system, 761–762
affecting phagocytosis, 745, 749–751
affecting serum urate, 714
analogues of, 744, 746
distribution in tissues, 744
in gout, 865–882
in acute gout, 752–756
prophylactic use of, 786, 802, 814, 821
of sacroiliac joint, 712, 713
in secondary gout, 766
in gouty arthritis, acute, 912
in inflammatory response to microcrystalline sodium urate, 717, 721, 752
inhibiting chemotaxis of leukocytes, 746, 757–759
in nonurate crystal-induced synovitis, 763
phagocytosis by, suppression of, 1112–1121
in rheumatoid arthritis, 762, 763, 764
in sarcoid arthritis, 763, 764
structure of, 744
therapeutic trial with, 762–763
and urate crystal formation, 717, 745
Colchicoside, 744, 746
Colitis, ulcerative
acute phase reactant test in, *429*
antinuclear factors in, 1082
Collagen
synthesis of, hydralazine affecting, 69–74
in tophi, 738
Colloid osmotic pressure of synovial fluid, in rheumatoid arthritis, 29–37
Complement
and agglutination enhancing activity of rheumatoid factor, *467*
component activity in serum and synovial fluid, 219–230
first component in latex fixation test, *441*

Complement—*(Continued)*
and incomplete antibodies, 1094–1103
rheumatoid factors affecting levels of, *438*
Concreting acid, 603–604
Conduction defects, cardiac, in ankylosing spondylitis, *476*
Connective tissue disorders
direct Coombs reaction in, *457*
microcirculation of skin in, *469*
Coombs reactions, direct, in connective tissue diseases, *457*
Copper ligand excretion, in rheumatoid arthritis, *442*
Coronary heart disease, uric acid levels in, 847–848, 855, 857
Corticosteroid therapy. *See* Steroid therapy
Cortisol, and glycine incorporation into articular cartilage, *455*
Creatinine
clearance of
alcohol affecting. 787, 791
in fasting state, 803
in glycogen storage disease, 781
uricosuric agents affecting, 871, 876
uricosuric effect of, 688
Cricoarytenoid joint, rheumatoid arthritis of, cineradiography of, *441*
Cryoglobulinemia, vasculitis with. *456*
Cystinosis in childhood, 693
Cytochrome oxidase, and uric acid oxidation, 701
Cytoplasmic fluorescence, studies of, 213–218

DBA/2JN mice, sex hormones, bone changes and osteoarthritis in, 1027–1037
Degenerative joint disease
and complement in synovial fluid, 222
sacroiliac, *462*
salicylates affecting, 960–968
Dehydration, urate levels in, 797
Dehydrogenase, isocitric, levels in rheumatic disorders, *440*
Deoxyribonucleic acid
antibody in lupus erythematosus, 213–218, *446*
particles in synovial fluid, *460*
Desacetylmethyl colchicine, 744, 746
Desacetylthiocolchicine, 744, 746
Diabetes
acidosis in
and hyperuricemia, 800
polymorphonuclear leukocytes in, 844
and gout, 709, 853–864
Dialysis for uremia, and hyperuricemia, 840–845
Diazo-oxonorleucine, and uric acid production, 837, 883
Diazoxide, affecting uric acid excretion, 830
affecting uric acid levels, *454*
carbohydrates
tolerance in gouty subjects, 854, 860
and uric acid excretion, 800, 803, 815
fat intake affecting gouty subjects, 814, 815
high fat diet and hyperuricemia, 799–822
high purine, and uric acid excretion, 807–809
and hyperuricemia from alcohol, 786, 791, 795
low purine, and uric acid excretion, 680
protein intake
affecting urinary nitrogen, 618
and uric acid excretion, 800, 803, 815
ribonucleic acid feedings, effects of, 671–678, 680
Digestive juices, uric acid in, 699, 703
Diphenylhydantoin, lupus erythematosus from, 260–265
Disodium edetate, in scleroderma, 1145–1151
Diuresis, and urate accumulation, 691–692
Dolorimeter, for quantification of articular tenderness, 551–559

Ears, chloroquine affecting, *474*
EA-TDA, effects of, 827, 836–838
EDTA, in scleroderma, 1145–1151
Ehlers-Danlos syndrome, musculoskeletal signs of, *467*
Electron microscopy
of renal lesions from gold therapy, 1–11
of rice bodies from rheumatoid patients, 1053–1062
Embolization, fat
and avascular necrosis, *448*
in hypercortisonism, *447*
Endotoxin inactivation, in knee joints, *446*
Entrapment neuropathy, in rheumatoid arthritis, 294–301
Epidemiology of rheumatoid arthritis, 76–79
Epinephrine, and uric acid clearance, 824, 826
Epiphyseal cartilage, in rachitic rats, *447*
Epsilon amino caproic acid, in scleroderma, *465*
Erythrocytes

Erythrocytes—*(Continued)*
auto-antibody in NZB/Bl mice, *446*
direct Coombs reaction in connective tissue diseases, *457*
sensitized, reactions with rheumatoid factor, 203–211
Ethacrynic acid, urate-retaining effect of, 824
2-Ethylamino-1,3,4-thiadiazole, effects of, 827, 836–838
Exercise program with beach ball, *473*

Factor XII, urate crystals affecting, 741–743
Familial Mediterranean fever
arthritis of, *449*
joints in, *445*
Family studies
aggregation and rheumatoid disease, 418–425
of Marfan syndrome, *451*
Fasting, effects of. *See* Starvation
Fat
dietary, affecting gouty subjects, 814, 815
embolization
and avascular necrosis, *448*
in hypercortisonism, *447*
staining of bones for, *448*
Fatty acids, synthesis of, and alcohol oxidation, 789
Feces, uric acid in, 699, 700
Fibrils, amyloid, immunologic studies of, *435*
Fibrin, in rheumatoid synovitis, *463*
Flavoprotein-cytochrome electron transport chain, in alcohol oxidation, 789
Fluorescence
cytoplasmic, studies of, 213–218
studies with
of hyaluronateprotein in synovial lining cells, *432*
in lupus erythematosus, *443*
Formate, labeled, in purine biosynthesis studies, 656, 837
Frozen synovial fluid, microscopic evaluation of, *429*

Gamma globulin. *See* Globulin
Garrod, Alfred Baring, 605–608, 711, 714, 727, 733, 786
Globulin
anti-gamma-globulin activity in serum, *466*
anti-gamma-globulin factors in aging, 538–548
antinuclear factor in lupus erythematosus, *443*
circulating L-chains in serum sickness, *475*
cryoglobulinemia, 19S-7S type of, vasculitis with, *456*
detection of anti-globulin factors, 194–201
gamma globulin affecting rheumatoid factor, 50–59
gamma globulin metabolism in immunized rabbits, 38–48
reactions with rheumatoid factor, 50–59, 203–211
reactivity of 19S anti-gamma globulins with native 7S gamma globulins, *468*
in synovial fluids, 14–26
Watson's antiglobulin, *441*
Glomerular ultrastructural changes, in lupus erythematosus and NZB/BL mice, *436*
Glomeruli, hydroxylysine:hydroxyproline ratio in, *452*
Glomerulonephritis
from gold therapy, 1–11
reticuloendothelial system in, *465*
Glucose
hypoglycemia in glycogen storage disease, 781
infusions of, and uric acid excretion, 800, 805, 810, 811, 815
tolerance in gouty subjects, 854, 860
Glucose-6-phosphatase deficiency, and glycogen storage disease, 780
Glucose-6-phosphate, and purine production, 653
Glucose-6-phosphate dehydrogenase deficiency, as genetic trait, 633
Glutamic acid, and uric acid levels, 693, 800
Glutaminase, deficiency of, 654, 693
Glutamine
and biosynthesis of purine nucleotides, 610, 623, 652, 654
metabolism in gout, 614–621, 656
Glycerol, affecting uric acid excretion, 800
α-Glycerophosphate, and alcohol oxidation, 789
Glycine
deamination of, 615
incorporation of
into articular cartilage, cortisol affecting, *455*

Glycine—*(Continued)*
in glycogen storage disease, 783, 785
in polycythemia, 768
in psoriasis, 863
in uric acid production studies, 648–658, 663
tolerance test, in hyperuricemia, *449*
and uric acid excretion, 800
Glycogen storage disease, and gout, 780–785
Glycolic acid, affecting uric acid excretion, 800
Glycolysis, and synovial pH, 718, 740
Glyoxylic acid, formation of, 696
Gold therapy
renal lesions from, 1–11
in rheumatoid arthritis, effectiveness of, *469*
Gonococcal arthritis
in children, *442*
synovial pH in, 738
acidity of urine in, 620, 625, 670
acute, calcific tendonitis simulating, *475*
and alcohol use, *454*, 786–798
allopurinol in, 875, 883–910
See also Allopurinol
amino acid metabolism in, 614–621
ammonia excretion in, 624
ammonia production in, 614–621, 654
and atherosclerosis, 709, 852
back pain in, 712
BAL therapy, 745
and calcinosis, 730
colchicine in, 865–882
See also Colchicine
and complement in synovial fluid, 222
and diabetes mellitus, 709, 853–864
dietary factors in. *See* Diet
early theories of etiology and pathogenesis, 599–608
evolutionary aspects of metabolic defects in, 614–621, 667, 668, 670
food, fast and alcohol affecting uric acid levels in, *454*
glomerular filtration rate in, 668
glutamine metabolism in, 614–621, 656
and glycogen storage disease, 780–785
griseofulvin in, 880–881
and Hageman factor activation by urate crystals, 741–743
hemopoietic diseases with, 765–771
hereditary factors, 627–647
historical aspects of, 727–728
and hyperuricemia, 642, 729
See also Uric acid
indomethacin in, 881–882
See also Indomethacin
kidney in, 708–709, 711
See also Kidney
lactate infusions in, 794
larynx in, 1019–1026
and leukemia, 769, 775
lipid serum levels in, 709, 861
7-methylguanine excretion in, 655
microcrystalline sodium urate injections in, 361–366
mycoplasmas in, 380
myeloproliferative diseases with, 765–771, 777
normoexcretors of uric acid, 656–657, 665, 669, 685
pathogenesis of, 733
pathology of, 707–713
penicillamine in, 745
and pH of synovial fluid, 718, 736–739
phenylbutazone in, 872–873, 882, 908
platelets in, 713
podophyllotoxin in, 761
and polycythemia vera, 765–771, 775, 777
primary, treatment of, 911–920
probenecid in, 868, 875, 877
production of inflammatory reaction, 715–717, 720, 721, 725, 726–735
progressive nature of, with inadequate therapy, 80–90
and psoriasis, 863
of sacroiliac joint, 712
salicylates in, 866, 868
saturnine, 709
scintillation scanning of joints in, 976–987
in starvation, 988–996
sulfinpyrazine in, 85, 87, 868, 875, 877, 879, 908
thiophenylpyrazolidine in, 868
thread test in, 605
tophaceous. *See* Tophaceous gout
tophi in, origin of, 267–285
triglyceride levels in, 860–861
twin studies of, 629
urate crystals in, 707–708, 710–711
uric acid overproduction in, 648–664, 669
See also Uric acid
uricolysis in, 701
uricosuric agents in, 865–882
and urinary stones, 602, 603
See also Calculi
vascular disorders in, 709, 713, 878

Gonococcal Arthritis—*(Continued)*
vinblastine in, 760
vincristine in, 761
xanthine oxidase inhibitors in, 883–910
Gouty arthritis
aberrancy in hallmarks of, 998–1001
acute attack of, 714–725
acute phase reactant test in, *429*
bradykinin in, 720
colchicine in, 1112–1121
kinin peptides in, 720–721
and lactic acid in synovial fluid, 718
Granulomas
carrageenin, hydralazine action in, 69–74
in mycobacterial adjuvant disease, *452*
Griseofulvin, in gout, 880–881
Guanine nucleotides, action of, 611
Guanosine 5′-phosphate (GMP), production of, 610, 652

Hageman factor, urate crystals activating, 741–743
Hand
in rheumatoid arthritis, orthetic devices for, 1006–1018
surgery of, in rheumatic diseases, *456*
x-ray films of, *431*
Haptoglobin, in synovial fluid, in rheumatoid arthritis, 355–359
Hashimoto's disease, *458*
Heart conduction defects, in ankylosing spondylitis, *476*
Heart disease
with rheumatoid arthritis, 403–417
uric acid levels in, 847–848, 855, 857
Heberden's nodes, and abnormalities in other joints, *477*
Hemarthrosis, experimental, synovium in, *440*
Hemiarthroplasty, in rheumatoid knee, *472*
Hemodialysis for uremia, and hyperuricemia, 840–845
Hemolytic complement, in serum and synovial fluid, 219–230
Hemopoietic diseases, gout with, 765–771
Hemoproteins, and peroxidation of uric acid, 701
Hench, Philip Showalter, 573–576
Hepatitis, uric acid excretion in, 794
Hip joint, in Paget's disease, *454*
Histidine, affecting uric acid excretion, 800
Holbrook Memorial Lecture, 911–920
Homogentisic acid solutions, infra-red spectra of, 1002–1005

Hyaluronateprotein
in synovial fluid, *465*
in synovial lining cells, *432*
Hyaluronidase, and chondroitin sulfate loss from osteoarthritic cartilage, *433*
Hydralazine
affecting collagen synthesis, 69–74
syndrome from, 69, 260
Hydrogen, carriers of, in alcohol oxidation, 789
Hydroquinone, spectra of, 1002–1005
Hydroxyapatite crystal formation, 725, 730, 841
β-Hydroxybutyrate
and alcohol oxidation, 789, 791
and uric acid clearance, 781, 800, 819, 821
Hydroxychloroquine, reaction with isocitric dehydrogenase, *440*
Hydroxylysine, and hydroxyproline in glomeruli, *452*
Hydroxyproline
and hydroxylysine in glomeruli, *452*
urinary levels in osteoporosis, 61–67
4-Hydroxypyrazolo(3,4-d)pyrimidine (HPP). *See* Allopurinol
Hypoxanthine
and biosynthesis of purine nucleotides, 610, 612
excretion of, 616, 884
solubility of, 895

Imidazoleacetic acid ribonucleoside, excretion of, 652
Immune studies, in vasculitis with cryoglobulinemia, *456*
Immunized rabbits, gamma globulin metabolism in, 38–48
Immunobiologically active material in rheumatoid arthritis serum, *433*
Immunoconglutinin, *430*
Immunofluorescence studies
cytoplasmic fluorescence, 213–218
of hyaluronateprotein in synovial lining cells, *432*
Immunology
and steroid therapy of lupus erythematosus, 244–257
studies of amyloid fibrils, *435*
Inclusions, in synovial leukocytes, 511–522
Indomethacin
assessment of, *431*
in gout, 881–882
in rheumatic fever, 501–508

Indomethacin—*(Continued)*
in rheumatoid arthritis, *435*, 921–940
side effects of, 935–937
Inflammation
acute, experimental model of, *471*
from injected sodium urate crystals, 361–366, 715–717, 721, 725, 726–735, 752
of joints, in rheumatoid arthritis, 289–292
localized rheumatoid arthritis, *455*
Inflammation Units, in test for rheumatic disease, *429*
Influenza, Asian, and rheumatoid factor, 524–528
Inosine, and allopurinol therapy, 897
Inosine 5′-phosphate, increased synthesis of, 610
Insulin, effects in fasting state, 809–810, 814
Interstitial fluid of cartilage, movement of, 481–493
Intestinal tract, and uric acid elimination, 694–706
Intradermal tests in diseases, compared with antinuclear factors, *428*
Inulin clearance
infusions affecting, 819
and urate clearance, 673, 674, 678, 685, 687
Iodinated serum albumin, in rheumatoid arthritis joint studies, 976–987
Iron metabolism, in rheumatoid arthritis, 233–242
Isocitric dehydrogenase levels, in rheumatic disorders, *440*
Isoniazid, metabolism of, 632

Joints
cartilage studies, *445*
protein synthesis in, *451*
salicylates inhibiting degeneration of, 960–968
cortisol affecting glycine incorporation into cartilage, *455*
dolorimeter for quantification of tenderness in, 551–559
in familial Mediterranean fever, *445*
inflammation in rheumatoid arthritis, 289–292
lesions from Mycoplasma species, *457*
motion in rheumatoid arthritis, factors affecting, *444*
scintillation scanning of, in rheumatoid arthritis, *475*, 976–987
skin temperature in diseases of, *473*
Juvenile rheumatoid arthritis. *See* Rheumatoid arthritis

Kallikrein, in synovial fluid, 742
Kaolin, in Hageman factor deficiency, 743
Kellgren's arthritis, *461*
Ketones in blood, in glycogen storage disease, 781
Ketosis, and uric acid retention, 799, 800, 853
Kidney
alcohol affecting metabolism of, 796
function studies, and uric acid values, 643–644, 652
See also Uric acid excretion
gold therapy affecting, 1–11
in gout, 620, 624, 694, 708–709, 711, 767–768, 778
nephrolithiasis in secondary gout, 766–767
in scleroderma, *464*
tophi in, 877–878
tubular reabsorption of urate, 668–669, 679, 779, 874, 878
tubular secretion of uric acid, 665, 669, 679, 779
tubular transport of urate, 686–693, 800, 815, 822
urate nephrolithiasis in starvation, 988–996
uric acid nephropathy, 708, 718, 775
uricosuric agents affecting, 870–871, 873
See also Glomerulonephritis
Kinin peptides
in gouty arthritis, 720–721
in synovial fluid, 742
Knee
endotoxin inactivation in, *446*
metastases to patella, 560–567
rheumatoid, hemiarthroplasty in, *472*
staphylococcus suppurative arthritis in, 389–401

Lactate infusions, in gouty subjects, 794
Lactic acid
affecting uric acid excretion, 687, 688, 796, 800
blood levels
alcohol affecting, 787–791
in fasting subjects, 821
in glycogen storage disease, 781
colchicine affecting production of, 745
production by leukocytes, 747, 760
in synovial fluid in gouty arthritis, 718
and urate crystal formation, 734, 740
Larynx, gouty involvement of, 1019–1026
Latex fixation test, first component of complement in, *441*

Lead poisoning, and renal disease, 709
Leg ulcers, in rheumatoid arthritis, *443*
Leprosy, antinuclear factors in, *428*
Leukemia
  chronic, mycoplasmas in, 380
  colchicine derivative in, 761
  and gout, 769, 775
  uric acid levels in, 772–779, 877, 896–898
  and uric acid nephropathy, 708, 718
  xanthine oxidase inhibition in, 896–898
Leukocytes
  colchicine affecting, 745–753, 757–759, 1104–1111, 1112–1121
  in inflammatory response to crystal injection, 732–733
  lactic acid production by, 747, 760
  and phagocytosis of urate crystals, 701, 715, 717, 723, 727, 734, 742
  pyrogen formation by, 742
  from rheumatoid synovial effusions, *432*
  streptococcal antigens in cultures of, *437*
  synovial
    inclusions in, 511–522
    and pH in fluid, 718, 736
  trimethylcolchicinic acid affecting, 1104–1111
  uricolytic properties of, 701–702
Lipids
  serum levels in gout, 709, 861
  synthesis of, and alcohol oxidation, 789
  and uric acid levels, *430*
Lithic acid, 603
Lithium urate, intravenous infusions of, 678
Liver, alcohol affecting, 789, 794
Liver extract, hyperuricemia from, 825
Lung disease, rheumatoid, penicillamine in, *453*
Lupus erythematosus, systemic
  abnormal L.E. cell test with absence of antinuclear factors, *470*
  acute phase reactant test in, *429*
  antibodies in, *476*
    anti-DNA, *446*
    to ribosomes, 213–218
  from anticonvulsants, 260–265
  antinuclear factors in, *428*, *443*, *463*, 1080–1093
  extracellular material in cell preparations, *472*
  glomerular ultrastructural changes in, *436*
  intradermal tests in, *428*
  mycoplasmas in, 376–386
  NZB/NZW mice as model of, *441*
  reticuloendothelial system in, *465*
  and scleroderma, *450*
  steroid therapy of, 244–257
  syndrome resembling, from hydralazine, 69, 260
Lymph nodes, polyribosomes from, *459*
Lymphocytes
  protein synthesis by, in Waldenstrom's macroglobulinemia, *437*
  salicylates suppressing transformation, *442*
Lymphomas, xanthine oxidase inhibition in, 896–898
Lysis of patella, from metastatic carcinoma, 560–567

Macroglobulinemia
  of infectious mononucleosis, *477*
  Waldenstrom's, and protein synthesis by lymphocytes, *437*
Mannitol diuresis, and urate accumulation, 691–692
Marfan syndrome, family studies of, *451*
McCarty, Jr., Daniel J., 1161–1162, 1164
Mediterranean fever, familial
  arthritis of, *449*
  joints in, *445*
6-Mercaptopurine
  affecting EA-TDA action, 837
  in nephrotic syndrome, *468*
  xanthine inhibitor with, 883
Metastases to patella, 560–567
Methemoglobin, and uric acid oxidation, 701
Methotrexate, affecting EA-TDA action, 837
Methylene blue, affecting sodium urate crystal growth, 1125, 1129
7-Methylguanine, urinary, in gout, 655
7-Methyl-8-hydroxyguanine, excretion of, 777
Microcirculation of skin, in connective tissue disease, *469*
Microcrystalline sodium urate injections, response to, 361–366, 715–717, 721, 725, 726–735, 752
Molybdenum, and xanthine oxidase, 704
Mongolism, cervical spine in, *455*
Mononucleosis, infectious, macroglobulinemia of, *477*
Mucins, salivary, antigenicity of, *461*
Mucopolysaccharides, in rachitic tissue, 337–352
Muscles
  in Ehlers-Danlos syndrome, 467
  polymyalgia rheumatica, *470*
Myasthenia gravis
  antibodies in, *476*

Myasthenia Gravis—*(Continued)*
antinuclear factors in, 1082
Mycobacterial adjuvant disease, as model of rheumatoid disease, *452*
Mycoplasmas
isolation and characterization of, 376–386
and joint lesions in swine, *457*
Myeloproliferative disease, gout with, 765–771, 777
Myocardial infarction, and hyperuricemia, 847–848

Necrosis, avascular, and fat embolization, *448*
Nephrotic syndrome
antinuclear factors in, *428*
from gold therapy, 1–11
steroid-resistant, mercaptopurine in, *468*
Nerve entrapment, in rheumatoid arthritis, 294–301
Nervous system, colchicine affecting, 761–762
Neuropathic knee joints, staphylococcus suppurative arthritis in, 389–401
Nicotinamide, with EA-TDA, 836, 838
Nicotinamide adenine dinucleotide (NAD)
alcohol oxidation affecting, 789
thiadiazoles affecting, 838
Nicotinic acid, affecting EA-TDA action, 838
Nitrogen, distribution in urate molecule, 653–655
Nitrogenous waste, uric acid as, 614–621
Nocardia asteroides, and complement in synovial fluid, 225
Norepinephrine, and uric acid clearance, 824, 826
NZB/BL mice
glomerular ultrastructural changes in, *436*
red-cell auto-antibody in, *446*
NZB/NZW mice, as model of lupus erythematosus, *440*

Obesity, starvation in, and uric acid levels, 988–996
See also Starvation
Orotate sodium crystals, 716, 742, 750
Orotic acid, and purine synthesis, 664
Orthetic devices, for hand in rheumatoid arthritis, 1006–1018
Osmotic pressures of synovial fluid, in rheumatoid arthritis, 29–37
Osseous tissue, anabolic agents affecting, 955–959

Osteoarthritis
antinuclear factors in, 1082
and chondroitin sulfate loss from cartilage, hyaluronidase affecting, *433*
and complement in synovial fluid, 222
in DBA/2JN mice, 1027–1037
mycoplasmas in, 380
sacroiliac joints in, *462*
scintillation scanning of joints, 976–987
Osteoarthrosis, 568–572
and Heberden's nodes, *477*
primary generalized, *461*
Osteoporosis
of rheumatoid arthritis, 943–953
urinary hydroxyproline in, 61–67
Ototoxicity of chloroquine, *474*
Ouabain, and uric acid secretion, 688
Oxyphenbutazone, in acute gouty arthritis, 912
Oxypurine excretion, allopurinol affecting, 886, 893, 897, 905

Paget's disease, hip joint in, *454*
Para-aminohippuric acid, and urate clearance, 688, 689
Patella, lysis of, from metastatic carcinoma, 560–567
Penicillamine
in gout, 745
in rheumatoid arthritis, 1064–1079
in rheumatoid lung disease, *453*
Periarthritis, calcific, in multiple sites, *462*
Pericarditis, constrictive, and rheumatoid arthritis, 403–417
Peroxidase, and urate metabolism, 701, 823
pH
in gouty tophi, 736–739
and reseeding of uric crystals, 745
of synovial fluid, 718, 736–739
of urine in gout, 620, 625, 670
Phagocytosis
by colchicine, suppression of, 1112–1121
colchicine affecting, 745, 749–751
and lactic acid production, 747, 760
of urate crystals, 701, 715, 717, 723, 727, 734, 742
Phenobarbital, lupus erythematosus from, 260–265
Phenylacetic acid
affecting uric acid excretion, 800
spectra of, 1002–1005
Phenylbutazone
in acute gouty arthritis, 912
in gout, 872–873, 882

Phenylbutazone—*(Continued)*
allopurinol with, 908
in rheumatoid arthritis, *435*
Phosphate levels, and uric acid retention, 841–842
Phospholipids, in rachitic costochondral plates, 1039–1045
5-Phosphoribosylamine synthesis, 619, 624, 654
5-Phosphoribosylpyrophosphate (PRPP), 610, 619, 652, 654–655, 783
Phosphorus, and uric acid excretion, 829
Phosphorylase deficiency, and glycogen storage disease, 780
Physicians, relationship to citizens, 183–193
Platelets, in gout, 713
Pleuropneumonia-like organisms
isolation and characterization of, 376–386
and joint lesions in swine, *457*
Pleuropulmonary manifestations, in Sjögren's syndrome, *427*
Podophyllotoxin, in acute gout, 761
Polyarteritis, mycoplasmas in, 380
Polycythemia vera, and gout, 765–771, 775, 777
Polymyalgia rheumatica, *470*
Polyribosomes
and protein synthesis in spleen, *473*
from rabbit lymph nodes, *459*
Polysaccharides, in rachitic tissue, 337–352
Population studies of hyperuricemia, 627–647
Alaskan Eskimos, 632
Filipinos, 630, 632, 636, 640
Framingham Heart Study, 641–642, 644, 646, 795, 847
Hawaii State Hospital studies, 636
Maoris, 632, 794
Marshall Islanders, 631
Michigan studies, 634, 635, 637
in Surinam, 637
Tecumseh Study, 634, 635, 637, 641, 853
Potassium chloride
affecting uric acid excretion, 831–835
in thiazide hyperuricemia, 1134–1143
Prednisone
with allopurinol in leukemia, 896
in lupus erythematosus, 244–257
Probenecid
with allopurinol, 905
in gout, 85, 87, 868, 875, 877, 916
and urate infusions, 691
and uric acid secretion, 687, 688, 714
Protein
hyaluronate
in synovial fluid, *465*
in synovial lining cells, *432*
intake of
affecting urinary nitrogen, 618
and uric acid excretion, 800, 803, 815
rheumatoid factor-like, 38–48
in serum, in Sjögren's syndrome, 970–974
of synovial fluids, 14–26, *465*
synthesis of
in articular cartilage and synovium, *451*
by lymphocytes in Waldenstrom's macroglobulinemia, *437*
in spleen, and polyribosomes, *473*
Pseudogout, and complement in synovial fluid, 225
Psoriasis
and hyperuricemia, 863
vascular disease in, *430*
Psoriatic arthritis, acute phase reactant test in, *429*
Psychological factors, in juvenile rheumatoid arthritis, 1152–1158
Purine biosynthesis
allopurinol affecting, 893
inhibition of, 837, 883
Purine nucleotides, regulation of, 610–613, 652
first enzyme in, 611, 613, 652, 655
Pyrazinamide, and urate secretion, 669, 688–689, 824
Pyrazinoic acid, and urate excretion, 683, 687
Pyrazolopyrimidines, 883
Pyrogen formation by leukocytes, in phagocytosis, 742
Pyrophosphate
action of, 724, 725
microcrystals of, 742
Pyruvate, blood levels of, alcohol oxidation affecting, 790
Pyruvic acid, affecting uric acid excretion, 800

Radiology
cineradiography of rheumatoid arthritis of cricoarytenoid joint, *441*
of hands, *431*
in rheumatoid arthritis of cervical spine, *431*
Reiter's syndrome
and complement in synovial fluid, 223

Reiter's Syndrome—*(Continued)*
mycoplasmas in, 376–386
Reticuloendothelial system, in diseases of altered immunity, *465*
Rheumatic fever
acute phase reactant test in, *429*
indomethacin in, 501–508
reticuloendothelial system in, *465*
Rheumatoid arthritis
acute phase reactant test in, *429*
antinuclear factors in, *463*, 1080–1093
of cervical spine, radiology of, *431*
colchicine in, 762, 763, 764
and complement in synovial fluid, 223
and copper ligand excretion, *442*
of cricoarytenoid joint, cineradiography of, *441*
epidemiology of, 76–79
exercise program with beach ball, *473*
and familial aggregation, 418–425
frequency and duration of, *459*
gold therapy in
effectiveness of, *469*
renal lesions from, 1–11
hand in, orthetic devices for, 1006–1018
hand surgery in, *456*
and haptoglobin in synovial fluid, 355–359
and immunobiologically active material in serum, *433*
indomethacin in, *435*, 921–940
iron metabolism in, 233–242
isocitric dehydrogenase levels in, *440*
joint inflammation in, 289–292
joint motion in, factors affecting, *444*
juvenile
antinuclear factors in, 1082
prognosis of, *434*
psychological factors in, 1152–1158
of knee, hemiarthroplasty in, *472*
leukocytes from synovial effusions in, *432*
localized, *455*
lower extremity ulcers in, *443*
lung disease with, penicillamine in, *453*
morning stiffness of, *439*
mycoplasmas in, 376–386
and osmotic pressure of synovial fluid, 29–37
osteoporosis of, 943–953
penicillamine in, 1064–1079
and pericarditis, 403–417
peripheral, variability study in, 302–334
phenylbutazone in, *435*
and proteins in synovial fluid, 18
and rheumatoid factor titer changes, *466*
rice bodies in, 1053–1062
scintillation scanning of joints, *475*, 976–987
steroid therapy in, low dosage, *478*
synovial cell cultures in, 1047–1052
synovial pH in, 738
thiotepa in, 495–499
ulnar nerve entrapment in, 294–301
Rheumatoid factor-like proteins, 38–48
Rheumatoid factors
affecting complement levels, *438*
in aged persons, 538–548
agglutination enhancing activity of, complement affecting, *467*
clinical significance of, *428*
detection of, 194–201
and fibrin in synovial fluid, *463*
gamma globulin affecting, 50–59
and incomplete antibodies, 1094–1103
and influenza A2 virus, 524–528
in lupus erythematosus, *476*
multiplicity of, 203–211
in myasthenia gravis, *476*
prevalence in New England town, *435*
titer changes in rheumatoid arthritis, *466*
Rheumatoid nodules, experimental model of, *452*
Rheumatology
requirements for successful future of, 581–585
thesaurus of, 97–182
Ribonucleic acid
hyperuricemia from, 671–678, 680, 719
messenger, observations on, *459*
Ribonucleoside
imidazoleacetic acid, 652
uric acid, 613
Ribonucleotide feedback mechanism, and allopurinol action, 889, 897
Ribose-5-phosphate, activity of, 653
Ribosomes
antibody to, in lupus erythematosus, 213–218
polyribosomes
and protein synthesis in spleen, *473*
from rabbit lymph nodes, *459*
Rice bodies from rheumatoid patients, 1053–1062
Rickets
epiphyseal cartilage in, *447*
histology and biochemistry of tissue, 337–352
phospholipids in costochondral plates, 1039–1045

Sacroiliac joints
degenerative changes of, *462*
gout of, 712
Salicylates
affecting renal tubular transport, 822
with allopurinol, 905
and amino acid clearance, 693
in gout, 85, 87, 866, 868
and inhibition of cartilage degeneration, 960–968
suppressing lymphocyte transformation, *442*
and urate levels, 823, 827–829
Saliva, uric acid in, 703
Salivary mucins, antigenicity of, *461*
Sarcoid arthritis, colchicine in, 763, 764
Sarcoidosis, and hyperuricemia, 863
Saturnine gout, 709
Scintillation scanning, of rheumatoid arthritis joints, *475*, 976–987
Scleroderma
antinuclear factors in, 1082
disodium edetate in, 1145–1151
epsilon amino caproic acid in, *465*
and lupus erythematosus, *450*
patients dying with, *439*
renal involvement in, *464*
Septic arthritis, and complement in synovial fluid, 225
Serum sickness, circulating L chains in, *475*
Sex hormones, and osteoarthritis, in DBA/2JN mice, 1027–1037
Sicca syndrome. *See* Sjögren's syndrome
Sjögren's syndrome
antibodies in, 970–974
pleuropulmonary manifestations of, *427*
Skin
lower extremity ulcers, in rheumatoid arthritis, *443*
microcirculation of, in connective tissue diseases, *469*
temperature measurements in joint disease, *473*
Spine
cervical
in mongolism, *455*
rheumatoid arthritis of, radiology of, *431*
tophus reaction in, 712
Spleen
cells in, and inhibition of autoimmunity in A/J mice, *474*
protein synthesis in, and polyribosomes, *473*
Splint Clinic, function of, *464*
Spondylitis, ankylosing
cardiac conduction defects in, *476*
sacroiliac joints in, *462*
Staining of bones for fat, *448*
Staphylococcal infections, in rheumatoid arthritis, *432*
Staphylococcua arthritis
and complement in synovial fluid, 225
suppurative, in Charcot's joints, 389–401
Starvation
and lactate levels in blood, 821
uric acid levels in, *454*, 786, 792, 795, 799–822, 988–996
Steroid therapy
antianabolic action on osseous tissue, 955–959
failure of, in nephrotic syndrome, *468*
and fat embolization, *447*
hyperuricemia from, 825
long term, *444*
low dosage, in rheumatoid arthritis, *478*
in lupus erythematosus, 244–257
in rheumatoid arthritis, 921–940
Streptococcal antigens, in leukocyte cultures, *437*
Sulfinpyrazone
with allopurinol, 903, 905, 908
allopurinol compared with, 900
in gout, 85, 87, 868, 875, 877, 879, 916
and uric acid levels, 811–813, 815
zyloprim with, 908
Superanabolon, effects of, 955–959
Suppurative arthritis, in Charcot's joints, 389–401
Sweat, uric acid in, 700
Synovial fluid
cell cultures in search for virus in rheumatoid arthritis, 1047–1052
complement components in, 219–230
DNA particles in, *460*
frozen, microscopic evaluation of, *429*
haptoglobin in, in rheumatoid arthritis, 355–359
hyaluronateprotein in, *465*
kinin content of, 721
leukocytes in
inclusions in, 511–522
in rheumatoid arthritis, *432*
mycoplasma in, 376–386
osmotic pressure of, in rheumatoid arthritis, 29–37
pH of, 718, 736–739
proteins of, 14–26

Synovial Fluid—*(Continued)*
thiotepa affecting, 495–499
ultrasound in analysis of, 368–375
urate crystals in, 707, 715, 734
uric acid in, 723
Synovial lining cells, hyaluronateprotein in, *432*
Synovitis
nonurate crystal-induced, colchicine in, 763
rheumatoid, fibrin in, *463*
Synovium
in experimental hemarthrosis, *440*
protein synthesis in, *451*

Temperature of skin, in joint disease, *473*
Tenderness, articular, dolorimeter for quantification of, 551–559
Tendonitis, calcific, simulating acute gout, *475*
THAM, affecting sodium urate crystal growth, 1125, 1129
Thesaurus of rheumatology, 97–182
Thiadiazoles, affecting uric acid, 825, 836–839
Thiazides
and amino acid clearance, 693
hyperuricemia from, 824, 827, 829, 830
potassium chloride and ammonium chloride in, 1134–1143
Thiophenylpyrazolidine, in gout, 868
Thiotepa, affecting synovial fluid, 495–499
Thread test, in gout, 605
Thromboplastin, plasma antecedent (PTA), urate crystals affecting, 741, 742
Thymus, cells in, and inhibition of autoimmunity in A/J mice, *474*
Tophaceous gout
allopurinol in, 900, 903, 907–910
and glycogen storage disease, 782
in secondary gout, 766
uricosuric agents in, 865–882
without acute attack, 724
Tophi in gout, 605
collagen in, 738
development of, 714
origin of, 267–285
pH in, 736–739
prevention and treatment of, 915–919
serum urate levels affecting, 719
urate crystals in, 708, 734
in vertebral column, 712
Transaminases, in liver, 615
Transplant antigens, allogeneic, amyloidosis after, *438*
Traumatic arthritis
and complement in synovial fluid, 221
mycoplasmas in, 380
and proteins in synovial fluid, 18
Triamcinolone, in lupus erythematosus, 244–257
Triglyceride levels
in gout, 860–861
and uric acid levels, *430*
Trimethylcolchicinic acid, 744, 746, 761
affecting leukocytes, 1104–1111
Tropolone, effects of, 745
Tryptophan, affecting EA-TDA action, 838

Ulcers, lower extremity, in rheumatoid arthritis, *443*
Ulnar nerve entrapment, in rheumatoid arthritis, 294–301
Ultrasound, in synovial fluid analysis, 368–375
Urea
and urease action, 704
and uric acid catabolism, 696, 697
Urease, gastric, 704
Uremia
with calcinosis and acute gout, 730
hyperuricemia with, 724, 840–845
microcrystalline sodium urate injections in, 361–366
Ureotelism, 616, 618
Uric acid and urates, 603
allopurinol affecting production of, 875, 891–895
and alloxan formation, 701, 705
and amino acid serum levels, 692–693
in bile, 703, 704
biosynthesis of
increased by thiadiazoles, 836–839
in leukemias, 772–779, 877, 896–898
calculi. *See* Calculi, uric acid
clearance of
in glycogen storage disease, 781
low purine diet affecting, 680
in secondary gout, 778
and serum levels, 682–683
crystals
activating Hageman factor, 741–743
amorphous material, 716, 717, 730, 742
in avascular area, 733
colchicine affecting response to, 717, 752
in gout, 267–285, 707–708, 710–711
inflammatory response to microcrystals,

Uric Acid and Urates—*(Continued)*
361–366, 715–717, 721, 725, 726–735, 752
inhibition of growth of, 1123–1133
microcrystalline injections in hyperuricemia, 361–366
phagocytosis of, 701, 715, 717, 723, 727, 734, 742, 749–751
reseeding of, 734, 745
in synovial fluid, 707, 715, 718, 734, 736
in vascular area, 734
in digestive juices, 699, 703
diuresis affecting accumulation of, 691–692
excretion of
alcohol affecting, 787–789, 791–794
allopurinol affecting, 682
diurnal variations in, 680–681, 814
drugs affecting, 686–688
extrarenal, 695, 699, 702, 705, 767, 768
and glomerular filtration, 665, 779, 800, 815, 874
in gout, 653–654, 665–670, 671–678
lactate affecting, 796
in normal and gouty man, 665–670
pyrazinoic acid affecting, 683, 687
and renal function, 643, 823
in feces, 699, 700
and gout, 605, 610, 642, 648–664, 669, 729
hyperuricemia
age and sex factors in, 641
alcohol-induced, 786–798
and amino acid serum levels, 693
and atherosclerosis, 852
and cholesterol levels, 849–851
and coronary disease, 847–848, 855, 857
and diabetes, 853–864
from drugs, 823–829
glycine tolerance test in, *449*
in glycogen storage disease, 780
and gout incidence, 642, 648–664, 669, 729
heredity of, 627–647
from high fat diets, 799–822
and hypertension, 846
kidney role in, 665, 694, 708, 715, 779
in leukemias, 772–779, 877, 896–898
in nongouty subjects, 645–646, 714
and psoriasis, 863
from RNA feedings, 671–678, 680, 719
and sarcoidosis, 863
in secondary gout, 767–768, 778
in starvation, 799–822
from thiazide, potassium chloride and ammonium chloride in, 1134–1143
twin studies of, 629
in uremia, 724, 840–845
in Wilson's disease, 695
infusions of, and serum uric acid levels, 678, 690–691
intestinal tract role in elimination of, 694–706
metabolism defect with cerebral function disorder, 659–663
nephropathy from, 775
as nitrogenous waste, 614–621
normoexcretors in gout, 656–657, 665, 669, 685
plasma concentrations, 666, 667, 670, 671
in leukemias, 779
and purine biosynthesis, 610–612
renal function affecting levels of, 643–644, 665, 694, 708, 715, 779
in saliva, 703
serum levels
and acute gouty arthritis, 724
food, fast and alcohol affecting, *454*
with glucose-6-phosphatase deficiency, 780
and lipid concentrations, *430*
in secondary gout, 767
in starvation, 988–996
and tophaceous deposits, 719
after urate infusions, 678, 690–691
sodium urate
inflammatory response to, 361–366, 715–717, 721, 725, 726–735, 752
solubility in serum, 718
subcutaneous injections of, 716, 725, 727, 752
types of deposition, 733–734
solubility in serum, 718
in sweat, 700
in synovial fluid, 723
in tophi, 705–706
tubular reabsorption of. *See* Kidney
turnover rate in gout, 658
urolithiasis in gout, 919–920
Uricase, absence of, in human tissues, 667, 668, 670, 701, 749, 823
Uricogenic agents, 836–839
Uricolysis, 694–702
colchicine affecting, 749–750
products of, 696–698
in renal disease, 701
site of, 698–700

Uricolysis—*(Continued)*
in tissues, 701–702
Uricosuric agents, 823, 915–919
in gout, 85, 87, 865–882
substances similar to, 815–816
Uricotelism, 616, 618, 708

Variability study, in peripheral rheumatoid arthritis, 302–334
Vascular disorders
in gout, 709, 713, 878
in psoriasis, *430*
Vasculitis, with cryoglobulinemia, *456*
Vertebrae. *See* Spine
Vinblastine, in acute gout, 760
Vincristine, in acute gout, 761
Viral infections
acute, mycoplasmas in, 380
rheumatoid factor and influenza, 524–528
Viruses, and synovial cell cultures in rheumatoid arthritis, 1047–1052
Viscosity of synovial fluid, ultrasound affecting, 368–375
Von Gierke's disease, 780

Waaler-Rose test, new method for, 530–536
Waldenstrom's macroglobulinemia, and protein synthesis by lymphocytes, *437*
Water diuresis, and urate accumulation, 691–692
Watson's antiglobulin, *441*
Wilson's disease, uric acid excretion in, 695

Xanthine, solubility of, 895
Xanthine oxidase
distribution in tissues, 703–704
inhibitor of, 682
in gout, 883–910
in leukemias and lymphomas, 896–898
preventing uric acid nephropathy, 776
Xanthinuria, 616
allopurinol in, 891–895
chlorothiazide in, 827
and stone formation, 898

Zoxazolamine, as uricosuric agent, 876
Zyloprim, anturane with, in gout, 908